Holen Sie sich die Stockscreener-App
157.55
1.13%
-2.49
Überblick
Nachrichten
Preisverlauf
Optionskette
Warum fällt AZN?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Astrazeneca Plc Aktie (AZN) Neueste Nachrichten
AstraZeneca stock gains analyst support as RBC sets 14,500p target - AD HOC NEWS
AstraZeneca COPD data back Citi's $7b peak sales case - Proactive Investors
RBC Capital Markets Initiates AstraZeneca Coverage at Outperform - marketscreener.com
AstraZeneca stock holds after RBC starts coverage at GBP145 - AD HOC NEWS
NEWSLETTER: AstraZeneca drug reduces lung disease flare-ups in late-stage trials - Reuters
RBC Initiates AstraZeneca at Outperform With GBP145 Price Target - marketscreener.com
Amgen, AstraZeneca combination improves survival measures in late-stage lung cancer study - Yahoo Finance
Amgen and AstraZeneca report survival improvement in lung cancer trial - Yahoo Finance UK
RBC Capital initiates AstraZeneca stock at Outperform, sets target at £145 By Investing.com - Investing.com Canada
RBC Initiates AstraZeneca at Outperform as Near-term Overhangs Create 'Attractive' Entry Point - marketscreener.com
Amgen and AstraZeneca report positive lung cancer trial results By Investing.com - Investing.com Nigeria
AstraZeneca stock edges lower ahead of the open after Imfinzi trial win - AD HOC NEWS
Amgen and AstraZeneca report positive lung cancer trial results - Investing.com
AstraZeneca Stock: What’s Shaping Investor Attention? - Kalkine Media
AstraZeneca stock heads into the open after a 1.2% slide - AD HOC NEWS
FDA clears Astrazeneca's Etcamah for first-line breast cancer - bioworld.com
AstraZeneca PLC : Gets a Buy rating from RBC - marketscreener.com
AstraZeneca PLC (AZN) Presents at European Respiratory Society (ERS) CongressSlideshow - Seeking Alpha
AstraZeneca stock dips as new cancer and lung trials reshape the pipeline - AD HOC NEWS
AstraZeneca reports tozorakimab COPD trial results - grafa.com
Astrazeneca Secures FDA Approval for New Breast Cancer Treatment - Benzinga
AstraZeneca PLC : Buy rating from JP Morgan - marketscreener.com
ERS 2026: AstraZeneca’s IL-33 inhibitor tozorakimab reduces mucus plug burden in COPD - Pharmaceutical Technology
AstraZeneca's Tozorakimab Shows Promise in COPD Trials, Stock Po - GuruFocus
AstraZeneca and Amgen clear a milestone in small cell lung cancer - marketscreener.com
AstraZeneca’s Lung Disease Drug Shows Broad Benefit in Trials - Bloomberg.com
AstraZeneca's drug combo helps lung cancer patients live longer in late-stage study - London South East
AstraZeneca's Imfinzi Combo Therapy Boosts Survival in Late-stage Small Cell Lung Cancer Study - marketscreener.com
AstraZeneca hails tozorakimab licence application approval in US - London South East
AstraZeneca's cancer drug combo hits main survival goal in late-stage trial - marketscreener.com
AstraZeneca (AZN) says Imfinzi combo extends survival in small cell lung cancer - Stock Titan
AstraZeneca (LSE:AZN) slumps today as combination chatter grips London pharma? - Kalkine Media
REGAstraZeneca PLCImfinzi+Imdelltra improved OS in small cell lung - TradingView
AstraZeneca Says Tozorakimab Cuts COPD Exacerbations in Phase 3 Trials - marketscreener.com
AstraZeneca PLC (AZN.L) stock price, news, quote and history - Yahoo Finance UK
Merck Trading Near 52-Week High: Is the Stock a Buy, Hold or Sell? - Zacks Investment Research
AstraZeneca's Tozorakimab Shows Statistically Significant Efficacy in Late-stage Trials - marketscreener.com
AstraZeneca moves forward in COPD - marketscreener.com
AstraZeneca’s COPD drug scores two late-stage trial wins as full data boosts blockbuster hopes - CNBC
AstraZeneca sees positive result in lung disease drug trial - Breakingthenews.net
AstraZeneca's COPD drug scores two late-stage trial wins as full data boosts blockbuster hopes - CNBC
New AstraZeneca (AZN) breast cancer treatment gets accelerated FDA nod—but only for some patients - Stock Titan
AstraZeneca PLC : Receives a Sell rating from Deutsche Bank - marketscreener.com
AstraZeneca PLC : Barclays maintains a Buy rating - marketscreener.com
AstraZeneca stock heads into the open after a 0.3 percent gain - AD HOC NEWS
Radioligand Therapy Market to Grow from USD 2.98 Billion in 2025 to USD 15.85 Billion by 2035, at a CAGR of 18.2% - GlobeNewswire Inc.
AstraZeneca stock gains on FDA breast cancer approval and analyst support - AD HOC NEWS
AstraZeneca Secures FDA Nod for New Breast Cancer Therapy Etcamah - The Globe and Mail
Citi backs AstraZeneca sentiment boost after Etcamah wins accelerated FDA approval - Proactive financial news
AstraZeneca stock gains on analyst support and July results - AD HOC NEWS
Why Is AstraZeneca (LSE:AZN) Back in Focus After Fresh Regulatory News? - Kalkine Media
AstraZeneca PLC (AZN) Stock Analysis: Unpacking a 30% Potential Upside with Strong Buy Ratings - DirectorsTalk Interviews
FDA approves AstraZeneca’s Etcamah combo for advanced breast cancer - Pharmaceutical Technology
AstraZeneca's breast cancer drug granted accelerated approval in the US - Sharecast.com
AstraZeneca PLC : Gets a Buy rating from JP Morgan - marketscreener.com
AstraZeneca’s Etcamah Approved In US For ESR1-mutated Advanced Breast Cancer - DirectorsTalk Interviews
A green light from the US FDA for AstraZeneca in breast cancer - marketscreener.com
AstraZeneca PLC : Jefferies reaffirms its Buy rating - marketscreener.com
AstraZeneca stock heads into the open after a 1.15 percent drop - AD HOC NEWS
IN BRIEF: AstraZeneca wins US nod for Etcamah breast cancer combo - London South East
AstraZeneca stock reacts as FDA grants accelerated approval for new breast cancer pill - AD HOC NEWS
AstraZeneca's Etcamah Combination Authorized for Advanced Breast Cancer Treatment in US - marketscreener.com
AstraZeneca’s breast cancer pill gets FDA approval - The Seattle Times
AstraZeneca's Breast Cancer Pill Gets Approval From The FDA - NDTV Profit
FDA Clears AstraZeneca's Breast Cancer Pill Etcamah - Briefs Finance
AstraZeneca’s Breast Cancer Pill Gets Approval From the FDA - Bloomberg.com
AstraZeneca wins approval of camizestrant for breast cancer (NYSE:AZN) - Seeking Alpha
AstraZeneca slides Friday, underperforms market - MarketWatch
0.80%
0.46%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):